New Jersey Legislature Passes Key ALS Legislation

In a big win for the ALS community, New Jersey has passed and signed into law legislation that will strengthen how amyotrophic lateral sclerosis (ALS) and related motor neuron diseases are tracked across the state. What started as Senate Bill S4030 — championed by Senators Vin Gopal and Troy Singleton — is now a legal requirement for health care professionals to confidentially report diagnosed cases of ALS to the State Health Assessment Data System.

The law, signed by Governor Phil Murphy on January 20, 2026, marks a major step forward in improving public health surveillance, expanding research opportunities, and ultimately enhancing support for people living with ALS and their families.

ALS is a rare, progressive neurological condition that attacks the nerve cells responsible for voluntary muscle movement. There is currently no cure, and experts have long believed ALS is underreported because of gaps in data collection.

What the New Law Does:
Mandatory Confidential Reporting: Health care providers who diagnose or treat ALS and other motor neuron diseases must now confidentially report cases to New Jersey’s State Health Assessment Data System. The reporting must occur within six months of diagnosis and is subject to strict privacy safeguards.
Stronger Data for Research: The collected information — de-identified to protect patient privacy — will be used for public health monitoring, research, and statistical analysis. Researchers and qualified public health officials will have access to the data to better understand the disease’s prevalence and progression.
Transparency and Access: As part of the law’s implementation, de-identified data and summary information will be made available to the public via the Department of Health’s website, giving advocates, scientists, and policymakers a clearer picture of ALS in New Jersey.

Sponsors say the law will close a critical gap in how ALS is understood at the state level and help position New Jersey to contribute to national research efforts. They also note that accurate, comprehensive data is crucial to improving care, securing resources, and shaping policy that benefits patients and families affected by ALS.

With broad bipartisan support and final enactment by the governor, New Jersey now joins a growing list of states taking proactive steps to better track and fight ALS — a win advocates say could make a big difference for the ALS community.